DarioHealth Corp. is pivoting from an investment phase to a compounding growth phase, centered on account depth, distribution efficiency, AI leverage, and value chain participation. The company exited pharmaceutical services revenue in favor of higher-quality, recurring B2B2C revenue streams, contributing to a 21% year-over-year reduction in operating expenses and a gross margin improvement to 62%. Management expects $13.1 million in contracted and late-stage annual recurring revenue to begin converting in the second half of 2026, with the majority of impact in 2027, and projects DarioIQ AI capabilities will add an incremental 10% to 15% in recurring revenue from existing customers. A structural shift toward channel-enabled distribution has resulted in 75% of new accounts coming through partners, lowering customer acquisition costs, while new products Dario Women and Dario Sleep are expected to contribute revenue in the fourth quarter of 2026. The company closed a $22.8 million registered direct financing in July, bringing its pro forma cash position to $36.8 million to support the path to cash flow positivity.
DarioHealth CorpCompany pivots to higher-quality recurring revenue, cuts opex, improves margins, and secures financing to support growth.